Alexandra Rogers, MD
Urology · Lafayette, CONPI 1093954497
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $348,346 of the $476,188 with a category attached, or 73.2%. Valencia Technologies Corporation accounts for 67.9% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2023 at $265,659 and has fallen 76.9% since, to $61,332 in 2025. Among urology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 465 payments — averaging $1024.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Valencia Technologies Corporation$323K
- Medtronic$65K
- Sumitomo Pharma America, Inc.$40K
- Axonics, Inc.$23K
- Urovant Sciences Inc$23K
- C. R. Bard, Inc. & Subsidiaries$393
- plus $2K from 28 others
Across 32 payments — averaging $476.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Axonics, Inc.$15K
Across 4 payments — averaging $12,500 each. An ownership or investment interest held by the physician or an immediate family member.
- Valencia Technologies Corporation$50K
What the payments were for
- Consulting fees$348,34673%
- Speaking & faculty fees$80,70117%
- Travel & lodging$37,3378%
- Food & beverage$9,1822%
- Education$6230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Valencia Technologies Corporation | 49 | $323,380 |
| Medtronic(2 entities) | 175 | $64,530 |
| Sumitomo Pharma America, Inc. | 63 | $40,429 |
| Axonics, Inc. | 79 | $22,619 |
| Urovant Sciences Inc | 25 | $22,555 |
| C. R. Bard, Inc. & Subsidiaries | 3 | $393 |
| BD | 1 | $380 |
| AbbVie(2 entities) | 11 | $270 |
| Boston Scientific | 5 | $202 |
| Astellas Pharma US Inc | 9 | $194 |
| Procept Biorobotics Corporation | 1 | $135 |
| Coloplast | 4 | $132 |
| Teleflex LLC | 4 | $131 |
| Biotissue Holdings Inc. | 1 | $122 |
| Ferring Pharmaceuticals Inc. | 7 | $111 |
| Pfizer | 6 | $102 |
| Innovation Technologies Inc | 2 | $58 |
| Bayer | 1 | $57 |
| Neotract Inc. | 3 | $54 |
| Olympus America Inc. | 1 | $44 |
| Revance Therapeutics, Inc. | 1 | $37 |
| Johnson & Johnson(2 entities) | 2 | $31 |
| Tolmar Pharmaceuticals, Inc. | 1 | $25 |
| Dendreon Pharmaceuticals LLC | 1 | $23 |
| Sagent Pharmaceuticals | 1 | $23 |
| Photocure Inc | 1 | $21 |
| Palette Life Sciences, Inc. | 1 | $20 |
| Dentsply IH Inc. | 1 | $20 |
| Dentsply IH AB | 1 | $18 |
| AMAG Pharmaceuticals, Inc. | 1 | $18 |
| Therapeuticsmd, Inc. | 1 | $17 |
| Mission Pharmacal Company | 1 | $15 |
| Foundation Medicine, Inc. | 1 | $14 |
| Cook Medical LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- eCoin Device Kit$322,814
- GEMTESA$62,212
- Axonics r-SNM System$18,073
- INTERSTIM$12,337
- ALTAVIVA$8,260
- Axonics$2,459
- Bulkamid$2,177
- AbsorbaTack$439
- NURO$400
- AquaBeam Robotic System$135
- NEOX$122
- CLARIX$122
- SOLYX$114
How this compares
$476,188 in reported general payments places this provider in the 95th percentile of 225 urology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 204 | $226,049 |
| Estradiol | 51 | $3,317 |
| Ciprofloxacin Hcl | 11 | $43 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $40,429 | $226,049204 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 225 urology providers in Colorado.
Other urology in Lafayette
- Julio ChongLafayette$36K
- Lawrence KarshDenver$706K
- Derek ZukoskyGolden$442K
- James McBrideDurango$234K
- Damian SorceParker$224K
- Suzanne MerrillLone Tree$102K
- Ali SarramLone Tree$76K
- John KeferBoulder$68K
- Garrick GreearLongmont$62K
- Nicholas WestfallGrand Junction$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.